Kisspeptin
Research OnlyAlso known as: KISS1, Metastin, Kisspeptin-54, Kisspeptin-10, KP-54, KP-10
An endogenous neuropeptide that serves as the master regulator of reproductive function. Acts upstream of GnRH to control puberty, fertility, and the menstrual cycle. Under clinical investigation as a safer IVF trigger and treatment for hypothalamic amenorrhea. Pioneering research led by Imperial College London.
Research Statistics
Well-characterized KISS1R signaling with 18 human studies across multiple countries; GPR54 mechanism is established in reproductive neuroendocrinology with strong independent replication.
Research Dossier
Overview
What is Kisspeptin and what does the research say?
Mechanism of Action
Kisspeptin is the master regulator of reproduction, acting as the upstream controller of the entire hypothalamic-pituitary-gonadal axis. Human clinical trials have established its physiological role and therapeutic potential.
How It Works (Simplified)
Kisspeptin serves as the gatekeeper of fertility by directly activating GnRH neurons:
Binds KISS1R on GnRH neurons, triggering Gq/11-coupled signaling cascade that causes calcium mobilization and GnRH release.
GnRH stimulates pituitary gonadotrophs to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in physiological pulses.
Kisspeptin neurons express estrogen and progesterone receptors, integrating sex steroid feedback to regulate ovulation timing.
Unlike hCG, kisspeptin produces a short-lived LH surge (hours vs days), eliminating ovarian hyperstimulation syndrome risk in IVF.
Scientific Pathways
KISS1R Signaling Cascade (GnRH Release)
Kisspeptin → KISS1R (GPR54) → Gq/11 → PLC activation → IP3 + DAG
↓
Ca2+ mobilization → GnRH neuron depolarization
↓
Pulsatile GnRH releaseReproductive Hormone Cascade (Downstream Effects)
Kisspeptin → GnRH release → Pituitary LH/FSH → Gonadal sex hormones
↓
Oocyte maturation / SpermatogenesisKey Research: Abbara A et al. (Imperial College London, 2017) demonstrated kisspeptin-54 as safe IVF trigger with zero OHSS cases. PMID:28854728
Important Limitations
- Clinical trials primarily conducted by single research group (Imperial College London)
- Long-term safety data not yet available
- Optimal dosing regimens still being refined
- Continuous administration causes tachyphylaxis (desensitization)
- Not yet approved by FDA or EMA; investigational use only
Evidence-Chained Benefits
Evidence-Chained Benefits
Research findings linked to mechanisms and clinical outcomes
What to Expect
Timeline based on observations from published studies. Individual responses may vary.
Single injection of kisspeptin-54 produces LH surge within 4-12 hours. Unlike hCG, the LH elevation is short-lived (hours rather than days), which eliminates OHSS risk in IVF applications.
During continuous infusion, LH pulsatility is restored within hours. In hypothalamic amenorrhea studies, 8-hour infusions produced sustained gonadotropin responses.
Effects are transient - kisspeptin's short half-life means hormonal effects normalize quickly after cessation. This is therapeutically advantageous for IVF safety but may limit other applications.
Research-Based Observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Quality Checklist
Visual indicators to help evaluate Kisspeptin product quality
Good Signs (6 indicators)
Warning Signs (4 indicators)
Bad Signs (5 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Peptide Interactions
Known and theoretical interactions when combining Kisspeptin with other peptides. Based on published research and mechanistic considerations.
Gonadorelin
SynergisticKisspeptin activates GnRH neurons upstream. Both stimulate the HPG axis but at different levels. Combined use may amplify gonadotropin release.
Clomiphene
CompatibleDifferent mechanisms for stimulating HPG axis - clomiphene blocks estrogen feedback, kisspeptin directly activates GnRH. May have additive effects on LH release.
Sermorelin
CompatibleDifferent hormonal axes - kisspeptin targets reproductive axis, sermorelin targets GH axis. No known interactions.
PT-141
CompatibleBoth affect sexual function but through different mechanisms - kisspeptin via limbic brain activity and hormones, PT-141 via melanocortin receptors.
Hcg
CautionBoth used for ovulation triggering in IVF. Kisspeptin produces shorter LH surge (safer for OHSS), while hCG produces prolonged stimulation. Combining may negate kisspeptin's safety advantage.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
References
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
Methodology Note
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Kisspeptin
Kisspeptin Calculators
Related Peptides
CJC-1295
DAC:GRF, Modified GRF 1-29, Tetrasubstituted GRF
A synthetic analog of growth hormone-releasing hormone (GHRH) with extended half-life. Limited clinical development; not approved for any indication.
Follistatin
FST, FS-344, FS-315 +1 more
An endogenous glycoprotein that inhibits myostatin and activin signaling, potentially allowing muscle growth beyond genetic limits. Gene therapy trials for muscular dystrophy show promise, but injectable peptide forms remain unapproved and understudied in humans.
GHRP-2
Growth Hormone Releasing Peptide-2, Pralmorelin, KP-102
A synthetic hexapeptide GH secretagogue with the strongest GH-releasing potency in its class. More potent than GHRP-6 with different side effect profile: less appetite stimulation but greater cortisol and prolactin elevation. Approved in Japan as Pralmorelin for GH deficiency diagnosis. Extensively studied in human pharmacology with robust clinical data.
GHRP-6
Growth Hormone Releasing Peptide-6, SKF-110679, Growth Hormone-Releasing Hexapeptide
A first-generation growth hormone secretagogue that stimulates GH release through the ghrelin receptor. Less selective than newer alternatives with effects on cortisol and prolactin. Historically significant as the peptide that led to ghrelin discovery. Cuban CIGB leads global cytoprotective research. Not approved for any indication.
Hexarelin
Examorelin, HEX, Growth Hormone Releasing Hexapeptide +2 more
The most potent synthetic GHRP (Growth Hormone Releasing Peptide), a hexapeptide that strongly stimulates GH release via the ghrelin receptor. Notable for cardioprotective effects independent of GH release. Development discontinued due to rapid desensitization with repeated dosing. Italian research leads global investigation.
HMG
Human Menopausal Gonadotropin, Menotropins, hMG +4 more
A urinary-derived glycoprotein hormone preparation containing both FSH and LH in approximately 1:1 ratio, FDA-approved for female infertility (ovulation induction, ART) and male hypogonadotropic hypogonadism. First used clinically in 1961 by Bruno Lunenfeld, HMG enabled the birth of the first American IVF baby in 1981 and remains a cornerstone of fertility medicine with over 60 years of clinical experience. Highly purified preparations (HP-hMG) demonstrate comparable or slightly superior live birth rates compared to recombinant FSH in IVF.